CMMB - CIK 0001534248
The table below shows Chemomab Therapeutics Ltd.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q2 2025 | Q1 2025 | Q2 2024 | Q1 2024 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | - | - | $2.93M | - | $5.02M | $6.89M |
| SG&A | - |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| $840.00K |
| - |
| $3.17M |
| $2.16M |
| Operating income | - | - | - | - | - | - |
| Income tax | - | - | $0.00 | - | $34.00K | $21.00K |
| Net income | -$2.06M | -$3.32M | -$3.63M | -$3.87M | -$7.97M | -$8.75M |
| EPS (diluted) | - | - | $0.01 | - | $0.04 | $0.04 |